Mitochondrial Metabolism Target Analysis: Advanced reagents for 2-oxodicarboxylate carrier research, rare metabolic disorders, and cancer metabolism studies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLC25A21 drug discovery. Select your research modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC25A21 Full-Length Recombinant Protein HEK293 expressed, Mitochondrial Carrier Domain, High purity (>95%), Endotoxin <1EU/µg, Sequence Verified |
View SLC25A21 Products |
| Gene Delivery | SLC25A21 Lentivirus Premade Particles Full-length ORF with CMV promoter, Puromycin resistance, for stable mitochondrial expression |
View SLC25A21 Products |
| Validator | SLC25A21 siRNA Set Three target-specific sequences for knockdown verification, >85% silencing efficiency validated by qPCR |
View SLC25A21 Products |
| Related Target A | DHTKD1 2-oxoadipate dehydrogenase (E1), pathway partner in lysine degradation |
View DHTKD1 Products |
| Related Target B | SLC25A1 Mitochondrial citrate carrier, SLC25 family homolog for counter-screening |
View SLC25A1 Products |
| Related Target C | OGDH Oxoglutarate dehydrogenase, metabolic node for TCA cycle integration studies |
View OGDH Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial Membrane Integration | Full-length protein expressed in HEK293 with native mitochondrial targeting sequence; Theoretical MW verified by MS |
| Transport Activity Measurement | Lentivirus-ready constructs for stable cell line generation; Compatible with radioactive 2-oxoadipate uptake assays |
| SLC Family Selectivity | Homolog panel available (SLC25A1, SLC25A22) for cross-reactivity screening; Sequence divergence mapped |
| Metabolic Pathway Validation | Matched DHTKD1 and OGDH proteins available for enzymatic cascade reconstruction |
| False Positives in Binding | Validated siRNA included for specificity confirmation in cellular context |
Live SLC25A21 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Metabolic Disease Research
- Cancer Metabolism Publications
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The scientific focus on SLC25A21 (mitochondrial 2-oxodicarboxylate carrier) is accelerating at the preclinical interface of rare metabolic disorders and oncology metabolism. Unlike surface receptor targets dominating immunotherapy pipelines, SLC25A21 represents an intracellular mitochondrial transporter critical for lysine degradation and TCA cycle anaplerosis. Current R&D activity centers on understanding 2-oxoadipic aciduria pathophysiology and exploring metabolic vulnerabilities in branched-chain amino acid-dependent tumors.
As precision medicine expands into mitochondrial medicine, the demand for high-fidelity SLC25A21 reagents is shifting from academic basic research toward pharmaceutical screening for small molecule modulators. The next wave of R&D targets allosteric inhibitors that disrupt 2-oxoadipate transport without affecting mitochondrial membrane potential.
Competitive Modality & Indication Snapshot
| Modality | Research Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | Allosteric inhibitors of 2-oxoadipate transport | 2-oxoadipic aciduria, Metabolic syndrome | Reconstituted transport assays using purified full-length protein (>95% purity) |
| Gene Therapy | AAV-mediated SLC25A21 correction | Rare inborn errors of metabolism | High-titer Lentivirus for cellular rescue validation studies |
| Metabolite Correction | Substrate reduction therapy | Lysine metabolism disorders | Pathway enzymatic assays requiring DHTKD1/OGDH co-reagents |
| Biomarker Development | 2-oxoadipate quantification methods | Diagnostic assays | Recombinant carrier protein for standard curve validation |